Bolsas y Mercados Españoles
Company
search
CLINICA BAVIERA, S.A.
AddressPO DE LA CASTELLANA 20, 28046 MADRID 
Listed Capital1,630,758.00 Euros

 


CLINICA BAVIERA
ISINES0119037010 TickerCBAV Nominal0.10 MarketContinuous Market Admitted Capital1,630,758.00 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
24/11/2017Close8.32008.32000.008.14008.14008.14008.140060488.40

Last pay
TypeEx-datePayment DateConcept
Dividend17/05/201719/05/2017Final 2016

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
 


 2017
until 24/11
2016201520142013
Capitalisation *
(thousands of euros)
135,679154,92288,713138,451170,577
Shares
(x 1,000)
16,30816,30816,30816,30816,308
Period Close Price
(euros)
8.32009.50005.44008.490010.4600
Period Last Price
(euros)
8.14009.50005.44008.490010.4600
Period High Price
(euros)
10.460010.15008.850012.170010.4600
Period Low Price
(euros)
8.02004.63004.40006.73003.6200
Volume
(thousands of shares)
15,7171,7461,2801,9842,367
Turnover
(thousands of euros)
162,16612,8188,97219,54814,898

Profile

CLINICA BAVIERA is the only European ophthalmic company listed in the Stock Exchange. It was born 25 years ago in Valencia (Spain), and nowadays it belongs to BAVIERA GROUP, with more than 70  clinics in Europe : Spain, Germany, Austria and Italy, and two different activities: ophthalmology and aesthetic medicine and surgery. 

BAVIERA GROUP has three business units: 

-          Ophthalmology Spain: 47 clinics.

-          Ophthalmology International: 3 clinics in Italy, 13 clinics in Germany, 5 clinics in Holland and 1 clinic in Austria.

-          Aesthetic medicine and surgery: 14 clinics in Spain.

In 1997, Clinica Baviera began its expansion plan through Spain, opening an average of 4 new clinics per year, being the leading Company in ophthalmology in Europe, offering solutions to solve myopia, hyperopia and astigmatism with refractive surgery, as well as intraocular treatments to correct cataracts and presbyopia, together with treatments to correct the rest of ophthalmic pathologies as glaucoma, vitreous-retina and strabismus.

Source: Issuing company.
25/11/2017 00:02:09

Research


To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © Bolsas y Mercados Españoles 2017